Loading...
Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:9 Issue:12 Number:24 ISSN#:2563-5476
RCT
ACE Report #12720
Ace Report Cover Arthroplasty

No Clinical Advantage of Sublingual Sufentanil vs Oral Oxycodone for Pain Management After TKA


How to Cite

OrthoEvidence. No Clinical Advantage of Sublingual Sufentanil vs Oral Oxycodone for Pain Management After TKA. ACE Report. 2020;9(12):24. Available from: https://myorthoevidene.com/AceReport/Report/12720

Study Type:Therapy
OE Level Evidence:1
Journal Level of Evidence:1

Sufentanil sublingual tablet system versus oral oxycodone for management of postoperative pain in enhanced recovery after surgery pathway for total knee arthroplasty: a randomized controlled study.

J Exp Orthop. 2020 Dec; 7: 92.

Contributing Authors: E Noel L Miglionico M Leclercq H Jennart JF Fils N Van Rompaey

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here

Synopsis

Seventy-two patients scheduled for a unilateral total knee arthroplasty were randomized to receive a sublingual sufentanil tablet system (15mcg) or oral oxycodone for post-operative pain management, in addition to a standardized multimodal analgesia protocol. The primary outcome of interest was pain on a numeric rating scale (NRS) at 24 hours post-operation. Secondary outcomes of interest included...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

LEARN MORE